Skip Navigation LinksHome > October 2005 - Volume 11 - Issue 5 > Rituximab in the Treatment of Refractory Dermatomyositis
JCR: Journal of Clinical Rheumatology:
Case Report

Rituximab in the Treatment of Refractory Dermatomyositis

Chiappetta, Nicole DO; Steier, James MD; Gruber, Barry MD

Collapse Box


Dermatomyositis is an inflammatory myopathy characterized by muscle weakness and inflammation. In contrast to polymyositis and inclusion body myositis, humoral immune mechanisms appear to contribute to the pathogenesis of dermatomyositis. A 56-year-old man with dermatomyositis resistant to conventional therapies was treated with 6 weekly infusions of the anti-CD-20 monoclonal antibody, rituximab, at a dosage of 100 mg/m2 in addition to other agents. The patient demonstrated a remarkable clinical response as indicated by an increase in muscle strength and a decline in creatine kinase enzymes. B-cell depletion therapy with rituximab used alone or in combination with other immunosuppressive therapies may be a viable option in patients with dermatomyositis as well as other autoimmune diseases refractory to current therapies.

© 2005 Lippincott Williams & Wilkins, Inc.

Follow Us!


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.